top of page

NCI-2022-08263

Updated: Feb 21

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer


This research study investigates whether combining SBRT for the primary lung tumor with concurrent mediastinal chemoradiation improves outcomes for patients with locally-advanced NSCLC compared to standard treatments. This refers to lung cancers that are more advanced than early-stage (stage I or II) but have not spread extensively to distant parts of the body (stage III). SBRT is a technique where very precise, high-dose radiation is delivered to the tumor, typically in a few (often 1-5) sessions. It's used for localized tumors and aims to deliver radiation with minimal damage to surrounding healthy tissue.


For more information about the trial, click the link below:

Clinical Trial Site: Einstein


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-02229

A Multicenter First-in-human Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the 5T4 Antibody-Drug Conjugate TUB-030 in Patien

 
 
 
NCI-2024-09407

A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced SolidTumors (The BREAKER-101 Trial) The BREAKER-101 trial is an early-stage (Phase 1a/1b) research study testing a new

 
 
 
NCI-2024-00437

A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMO

 
 
 

Comments


bottom of page